Browsing Tag
Tempus AI
21 posts
Why TEM stock sentiment could hinge on Tempus AI’s FDA-approved diagnostics expansion
Find out how Tempus AI’s xT CDx approval could strengthen TEM stock sentiment, oncology diagnostics growth, and ADLT pricing strategy.
Whitehawk Therapeutics (Nasdaq: WHWK) stock focus sharpens as ASCO 2026 data support SEZ6 ADC strategy in small cell lung cancer
Find out how Whitehawk Therapeutics’ SEZ6 data at ASCO 2026 could shape its HWK-206 ADC strategy in small cell lung cancer.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.
AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial
Avacta (AVCT) has treated the first patient in the FOCUS-01 Phase 1 trial of AVA6103, its Gen Two pre|CISION exatecan PDC. Initial data expected late 2026. Read more.
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts
Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology.
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.